# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
HC Wainwright & Co. analyst Joseph Pantginis reiterates Ligand Pharmaceuticals (NASDAQ:LGND) with a Buy and maintains $1...
Ligand Pharmaceuticals (NASDAQ:LGND) reported quarterly earnings of $3.84 per share which beat the analyst consensus estimate o...
Capital infusion will support botensilimab and balstilimab (BOT/BAL) clinical development, confirmatory Phase 3 trial, and lau...
Benchmark analyst Robert Wasserman reiterates Ligand Pharmaceuticals (NASDAQ:LGND) with a Buy and maintains $95 price target.
Captisol-enabled™ Topiramate Injection shown to be a substitute for an oral dose on a one-to-one basis
Pharmaceutical executive Scott Plesha named CEOLead product ZELSUVMI expected to be commercially available in late 2024Ligand P...
HC Wainwright & Co. analyst Joseph Pantginis reiterates Ligand Pharmaceuticals (NASDAQ:LGND) with a Buy and maintains $1...
Ligand Pharmaceuticals beats Q4 2023 sales estimates at $28.1 million, with strong core Captisol and royalty figures. CEO Todd ...